Expertise: To formulate a stable and inhalable aerosol formulation of the light-emitting particles and the in-vitro characterization of the resultant aerosol quality.

i2c Pharmaceutical Services is the trading name of Cardiff Scintigraphics (CSL), a spin-off company from Cardiff University established in 1992. It is now a niche specialist working in drug formulation, device development and research into analytical methods, having gathered expertise through involvement with more than 30 pharma and device companies.

i2c specializes in the design, conduct, analysis and reporting of clinical trials and in vitro studies, optimizing formulations and conducting clinical evaluations of inhaler systems such as pressurised metered dose inhalers (pMDI), dry powder inhalers (DPI) and nebulisers.

i2c worked with the UN Industrial Development Organisation (UNIDO) to help Egypt and Mexico fulfil their obligations to the Montreal Protocol in phasing out the use of CFCs in medicinal inhalers to benefit the environment and local pharma companies; it was shortlisted for a Queen’s Award for Enterprise (Innovation) in 2012; and Professor Taylor’s activities were cited as exemplary in the 2014 Research Excellence Framework impact case studies “Inhaled Medicines: Leveraging Benefits to Global Pharma and International Development”.

Glyn Taylor

Professor Glyn Taylor BSc, PhD is Emeritus Professor of Drug Delivery at Cardiff University and Chief Executive Officer at i2c. He has studied the mechanisms of aerosol deposition and drug absorption from the lung, and the scintigraphic imaging techniques used to quantify these parameters in clinical trials; his research led to the foundation of Cardiff Scintigraphics in 1992. He has lectured at academic and commercial conferences in UK, EU, US, MY and Australasia, supervised 20 PhD students and authored or co-authored more than 200 research articles on pharmacokinetics, biopharmaceutics and gamma scintigraphy. Glyn has served on an MHRA pharmacokinetics expert advisory group, consulted for pharma companies and delivered collaborative programmes with companies including AstraZeneca, GlaxoSmithKline, 3M, Novartis and Pfizer. His research has influenced the development of several marketed pharmaceutical products (Gaviscon Advance) and inhalation devices (Clickhaler and e-Flow).

Simon John Warren

Simon John Warren BSc, PhD is Research Manager at CSL and honorary lecturer at the Cardiff University School of Pharmacy & Pharmaceutical Sciences. He has extensive expertise in pharmaceutical formulation (inhalation and oral dosage forms), including small-scale concept and feasibility studies, technology transfer and industrial scale-up and clinical gamma scintigraphy applied to the development and testing of radiolabelled pharmaceutical dosage forms. In the latter, he has performed scintigraphic studies to enable the clinical evaluation of pulmonary delivery systems including pMDI, dry powder inhalers, nebulisers and condensation aerosol generator systems. He has also taken part in the development of a methodology for the appropriate radiolabelling of both novel and commercial comparator products to ensure that the radiolabel is an accurate surrogate for the active pharmaceutical ingredient / selected excipient and the formulation retains the aerosols characteristics of “off-the-shelf” products.

Cuong Hoa

Cuong Hoa BSc, PhD is Senior Research Scientist at CSL, honorary visiting lecturer at Cardiff University School of Pharmacy & Pharmaceutical Sciences and has 13 years’ experience in laboratory research in the pharmaceutical industry and academia. He took part in the UN-funded project to reformulate CFC-based inhalers in Article 5 countries and is experienced in analytical techniques, preparing guidelines/policies for Standard Operating Procedures (SOPs) and study protocols issued in accordance with good practice regulations. He is a proficient senior research scientist in conducting and designing laboratory techniques in line with standard pharmacopoeia methodologies ‒ ensuring testing conforms to SOPs ‒ technology transfer and scale-up of inhaled pharmaceutical products to overseas clients and inhaled pharmaceutical product registration for overseas markets.